Commentary on “Outcomes of Allogenic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation” JPEDSURG-D-25-00654R2

jpedsurg.org

The Vietnamese team led by Prof. Nguyen Thanh Liem contributes important work based on the cutting-edge application of cell-based therapy in biliary atresia (BA). This is, potentially, an exciting area working in a field characterised essentially by complete failure to influence the morbid march of liver fibrosis and ultimately failure of the post-Kasai (KPE) portoenterostomy child born with BA [1]. The 16 infants in the study group underwent KPE at a relatively advanced median age of 81 days with 75 % having severe fibrosis (METAVIR F3 or F4 (cirrhosis)) on the initial liver biopsy.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Sep 2025 · 1 min read

In brief

This commentary discusses Vietnamese research on umbilical cord mesenchymal stem cell infusion as adjunctive therapy for biliary atresia patients post-Kasai operation. The study addresses a critical unmet need in managing progressive liver fibrosis in infants with advanced disease at presentation.

Allogeneic umbilical cord mesenchymal stem cells show promise as adjunct therapy for post-Kasai biliary atresia patients with advanced fibrosis.
Study cohort had late Kasai operations (median 81 days) with 75% showing severe fibrosis (METAVIR F3-F4) at baseline.
Cell-based therapy represents novel approach to address liver fibrosis progression in biliary atresia, a condition with limited treatment options.
Vietnamese research team demonstrates feasibility of stem cell infusion in pediatric post-portoenterostomy liver disease management.

Written by the GCMD Library team from the article.

Read it at the source ↗